<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAST-F 2 of 11</td>
<td>Panel member request to consider listing “fluoropyrimidine and oxaliplatin” as a preferred perioperative chemotherapy regimen. Based on a review of the data, the panel consensus supported the continued listing of “fluoropyrimidine and oxaliplatin” as an option for perioperative chemotherapy and making it a “preferred” recommendation.</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
</tr>
</tbody>
</table>
|                           | Panel member request to consider if ECF and its modifications should continue to be included as perioperative chemotherapy treatment options for gastric cancer. Based on a review of the data, the panel consensus supported removing the following treatment options for perioperative chemotherapy:  
  - ECF (epirubicin, cisplatin, fluorouracil)  
  - ECF modifications (Epirubicin, oxaliplatin or cisplatin, fluorouracil or capecitabine) | 7    |
|                           |                                                                                                                                                                                                                                                                                                                                                        | 12   |
|                           |                                                                                                                                                                                                                                                                                                                                                        | 5    |
|                           |                                                                                                                                                                                                                                                                                                                                                        | 3    |
|                           |                                                                                                                                                                                                                                                                                                                                                        | 3    |